KPTI Institutional Ownership

KARYOPHARM THERAPEUTICS INC

Latest close $1.99 as of Aug 5, 2026

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Jul 28, 2026

Public consensus preview Reduction leaning 34/100 institutional research score

3 tracked institutions Latest filing Jul 28, 2026

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$3.65 52-week high$10.99

Latest close $1.99 0.0% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Jun 30, 2026

BlackRock Jul 28, 2026 filed

Goldman Sachs Group May 12, 2026 filed

JPMorgan Chase / Asset Management Oct 17, 2025 filed

T. Rowe Price Investment Management Jun 5, 2026 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 7 parsed filing(s) · 4 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
BlackRock CIK0002012383	Jun 30, 2026 observed Jul 28, 2026 filed · 28d Initial Schedule 13G	Initial Schedule 13G	1.3M	12.00%	$9.77	$7.09	$1.99
T. Rowe Price Investment Management CIK0001897612	May 31, 2026 observed Jun 5, 2026 filed · 5d Schedule 13G amendment	Reported reduction	1.5M -705.3K	12.00% 0.00 pts	$9.10	$9.08	$1.99
Goldman Sachs Group CIK0000886982	Mar 31, 2026 observed May 12, 2026 filed · 42d Initial Schedule 13G	Initial Schedule 13G	991	5.10%	$5.57	$8.92	$1.99

Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

SAMG SILVERCREST ASSET MANAGEME-A 34/100 Reduction leaning SBYSF SIBANYE STILLWATER LTD 34/100 Reduction leaning OTEX OPEN TEXT CORP 34/100 Reduction leaning ODD ODDITY TECH LTD-CL A 34/100 Reduction leaning

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026